OBJECTIVES The pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) is made up of 14 items that assess aspects of quality of life (Total) and a 1-item overall assessment (Overall). Quality of Life measures yield information independent of symptom measures. This post-hoc analysis investigated correlation between patient's QoL assessment and objective clinical assessment (YMRS, CGI-BP). METHODS A total 296 children (age 10-17) with bipolar disorder participated in a 4-week double-blind trial of aripiprazole (10 or 30 mg/day, fixed doses) vs. placebo (PBO). Completers entered a 26 week extension. Primary outcome was mean change on YMRS Total Score. Secondary measures included mean changes on CGI-BP Overall, PQ-LES-Q Total (T) and the Overall item (O). RESULTS YMRS Total and CGI-BP Overall improved vs. PBO with both doses of aripiprazole at week 4 and week 30 (p<0.05 and p<0.01 respectively, LOCF). Both aripiprazole arms improved on PQ-LES-Q(T) and (O); however they did not reach statistical significance. Observed Cases analysis (OC) demonstrated a correlation at week 4 and week 30 between % change in PQ-LES-Q(T) and % change in YMRS (r =-0.18 and -0.29, respectively; p<0.03). When 4 week YMRS Total improvement was put into categories (<20%; 20-30%; 30-50%; >50% reduction), % change in mean PQ-LES-Q(T) was 1.7, 2.3, 12.5, & 10.4 per category (trend analysis p=0.007; regression p=0.01; OC). At 30 weeks % change in mean PQ-LES-Q(T) was 3.3, NA, -2.6, 16.6 (p=0.02; Linear regression p=0.02; OC). When CGI-BP Overall was put into 4 categories (=0; -1; -2; ≤-3 point change) at 4 weeks, % change in mean PQ-LES-Q(O) was 0.02, 0.15, 0.27, 0.43 per category (trend analysis p<0.05; OC) and at 30 weeks, % change in mean PQ-LES-Q(O) was -1, 0, 0.63, 0.64 (p=0.02; OC). CONCLUSIONS In this trial of pediatric patients with BP there was positive correlation between patient-assessed QoL measures and clinician-based assessment.